{"type":"trials","record":{"id":41660,"source_id":"clinicaltrials-gov","external_id":"NCT05643118","title":"Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration","brief_summary":"This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, and Part B is a multiple ascending dose study. The primary objective is to evaluate the safety and tolerability of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD. The exploratory objectives are to evaluate the preliminary efficacy of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD, and to evaluate the pharmacokinetics (PK) of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Olix Pharmaceuticals, Inc.","enrollment":21,"countries":["United States"],"start_date":"2023-01-04","completion_date":"2025-11-10","last_update_date":"2025-12-11","source_url":"https://clinicaltrials.gov/study/NCT05643118","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Olix Pharmaceuticals, Inc.","interventions":["OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Best-corrected visual acuity (BCVA) — 28 days after last dose administration","Intraocular pressure (IOP) — 28 days after last dose administration","Slit lamp — 28 days after last dose administration","Fundus examination — 28 days after last dose administration","Spectral-domain optical coherence tomography (SD-OCT) — 28 days after last dose administration","Fluorescein angiography (FA) — 28 days after last dose administration"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05643118","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-01-04 to 2025-11-10","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.849Z","intervention":["OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)"],"participants":21,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Best-corrected visual acuity (BCVA) — 28 days after last dose administration","Intraocular pressure (IOP) — 28 days after last dose administration","Slit lamp — 28 days after last dose administration","Fundus examination — 28 days after last dose administration","Spectral-domain optical coherence tomography (SD-OCT) — 28 days after last dose administration","Fluorescein angiography (FA) — 28 days after last dose administration"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41660","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}